MedDataX Logo

The Influence of Chlorella Supplementation on Running Performance

NCT ID: NCT06479993

Last Updated: 2024-06-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-05

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Algae, such as chlorella, are gaining popularity as a nutritious additive to whole food or as a supplement. They contain a variety of beneficial nutrients like vitamins, minerals, healthy fats, and amino acids, which can have positive effects on our health and possibly athletic performance. Chlorella, specifically, is a type of single-celled green algae that you can easily find in health stores worldwide. While there's some evidence suggesting that chlorella supplementation might improve submaximal and maximal performance for cyclists, it's unclear if it has the same impact on runners. To investigate this, the investigators aim to conduct a double-blind randomised placebo controlled study to see if taking chlorella daily for 3-weeks can enhance different aspects of running performance, both during low/moderate and intense exercise, among individuals who regularly engage in running.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After signing the consent form, we will invite you to come to the ISEH laboratory on Tottenham Court Road so we can take some basic baseline readings. This should last up to 60 minutes and will also include a V̇o2max Test (visit 1). After this, you will be randomly allocated either start on chlorella or placebo first. After supplementation (for visit 2 and 3) you will be required to perform a submaximal running test which will entail running at 60% GET (gas exchange threshold), 80% GET, and 75% of the change from peak. This will then be shortly followed by an incremental test to fatigue.

You will then be required to undergo the exact same supplementation period on the alternative supplement with the same exercise test performed.

You will be required to come into the laboratory a total of 3 times. Each visit should take roughly 1 - 1.5 hours.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Athletes Healthy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Running VO2max Lactate Oxygen Consumption

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chlorella supplementation

Supplementation of chlorella (6g/day for 3-weeks)

Group Type EXPERIMENTAL

Chlorella supplementation

Intervention Type DIETARY_SUPPLEMENT

Supplementation with chlorella (6g/day for 3-weeks)

Placebo supplementation

Supplementation of placebo (6g/day for 3-weeks)

Group Type PLACEBO_COMPARATOR

Placebo supplementation

Intervention Type DIETARY_SUPPLEMENT

Supplementation with placebo - microcrystalline cellulose (6g/day for 3-weeks)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chlorella supplementation

Supplementation with chlorella (6g/day for 3-weeks)

Intervention Type DIETARY_SUPPLEMENT

Placebo supplementation

Supplementation with placebo - microcrystalline cellulose (6g/day for 3-weeks)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18-50.
* Run regularly (3-4 times a week).
* Train with a purpose to compete.
* Consider running to be your main sport.
* Be comfortable running continuously for over 30-minutes at moderate intensity.
* Represent a local running club.

Exclusion Criteria

* Individuals taking blood thinners.
* Known allergies to algae/mould and iodine.
* Any illness/conditions identified on PARQ (please see attached PARQ)
* Taking immunosuppressant medication
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University College, London

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tom Gurney

Role: PRINCIPAL_INVESTIGATOR

University College, London

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Colllege London (ISEH)

London, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tom Gurney

Role: CONTACT

Phone: 020 3447 2800

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tom Gurney

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

21745/002.1

Identifier Type: -

Identifier Source: org_study_id